This has been a trend almost for every month.
Funds readjust and mostly sell on last trading of the month and then buy at the first trading day of the month.
Control your temper cowboy.
This is not me that links LC to HZNP but some opportunists did when LC news was released on Nov 10 and the next day the stock was hit by 21% decline. A few tried to imply the same in past few trading days but there is no use. I am trying to tell some naïve trader/investors that LC is just a distributor that can be replaced. As a matter of fact, no company can deal with this situation better than HZNPN since the company has experience and tools from last year for the same scenario. The prove is in estimates and analysts recommendation. End of the story.
Revenue and income are raised compare to last Friday and last week.
You think that LC loss may affect HZNP business but this is not the case at all.
Today, DEPO has low volume and mostly retail players are trading.
I am wondering if DEPO goes different direction than HZNP.
If that is the case then next week when HZNP announces some acquisitions, it may affect DEPO PPS.
The most waiting acquisition may be announced on Monday. Yes, this Monday and I give it 95% chance.
That action will push the PPS to 200 MA which sitting close to $27.
It is in sane if anyone sell today and misses the big news.
Sentiment: Strong Buy
Ok, DEPO management but not its shareholders won a case against HZNP, but this does not help DEPO to do better marketing and sell more drugs.
Marc Wiener, Linden Care CEO, said, "We are disappointed in this ruling and believe we will prevail in arbitration proceedings. We are, and always have been, an independent specialty pharmacy under no manufacturer ownership or influence. Our work is critical to those in need."
Once Geri told you not to mix subjects. Finish a though before jumping to another.
Anyway, you seem to be angry at HZNP since DEPO is not doing well.
You may be right that DEPO won in court but it lost its shareholders confidence.
DEPO may know how to maneuver legal stuff but it is weak in marketing and drug sale.
It was an opportunity for DEPO shareholders to share HZNP success but DEPO management was thinking about their fat wallets more than the shareholders.
If HZNP could buy DEPO then its management could go after a different business, something that may know better. I think they could open a law firm, something they know much better than selling drugs and marketing.
What do you think? Just a free advice.
This is the most BS I have ever heard from somebody. Well, corvettecars also has the same wish as you. Probably, you were disappointed when shareholders yawned yesterday about court decision. I don't blame shareholders since no company in the sector is equipped to deal with these types of problems better than HZNP. HZNP is experienced in this area and it created PME for this purpose.
Today, HZNP was one of the best trading stocks with good volume. If the market didn't go flat one hour before the close, HZNP could end up with over 4% gain.
I think, one of Horizon's PME mission is to make sure that patients get their medication that doctors prescribe but not the ones that are decided by PBMs willfully for profit.
Man this PME has become a headache for PBMs and ES is afraid that other drug manufactures may follow HZNP sooner or later which put a big dent in ESRX and CVS profit.
What I reading is both parties will negotiate on something to not harm patients.
Meanwhile, HZNP will get other distributors involved in delivery of its drugs.
I know, this lady is dangerous and she does every thing for money.
She is getting money from rich Arabs, the same people who support ISIS too.
LC is a distributer for many pharmas and it handles less than 5% HZNP business.
On the other hand, HZNP is using several different distributers (specialty pharmacy if you want to call it), even one from ES.
If LC wins/lose or something in between, it has no effect on HZNP and the company will find other distributors. I think HZNP has already started to diversify and to increase it distributors. It indicated that it will do business with over 10 of them.
Nucynta was not created by JNJ but a German company. DEPO has to pay double digit royalty to the German company.
No, the PP will deter any attempt by any company.
You have to wait until paint dry in a few years.
This is what you gets and if something happens like a competition for Nucynta then DEPO will be dead.
Street follows its profit instead of helping shareholders. It probably shorted HZNP and now wants to get out at lower losses. Follow established analysts instead of for profit opinion.
DEPO current non-gap estimate for 2016 is $1.87 per share.
With 66 diluted DEPO shares, income for 2016 = $1.87 * 66m = $123m
HZNP has 160m shares and $2.09 income for 2016
HZNP non-gap income = $2.09 * 160m = $334m
Total HANP+DEPO income = $334 + $123 = $457m
DEPO has about 20m shares of convertible
Total DEPO shares to be converted to HZNP = 66m + 20m = 86m
If converted to HZNP shares at 0.95 then it will be about 82m shares of HZNP.
Total HZNP + DEPO shares = 160m + 82m = 242m
Combined PPS = $457m /242m = $1.88 per share
So, the combined PPS for 2016 is less than HZNP alone.
Now add DEPO debt and other expenses that eat up the cash flow.
However, the most difficult one will be integration of two companies
No assets that have single or zero growth.
Many more opportunities.
DEPO price was expensive, very expensive.
I think, this will help HZNP to focus on current business and add other potential acquisitions.
Hey, we may see one in a short time.
Sentiment: Strong Buy
VRX debt was upgraded.
In addition, CITI analyst says that selling is overdone.
The pop will happen to HZNP one of these days when an analyst comes to his/her senses and clear cloud for investors.